IL17A and psoriasis: While, Secukinumab (CosentyxTM) is the first fully human monoclonal immunoglobulin G1κ antibody targeting human IL-17A, with indications for psoriasis, psoriatic arthritis, and ankylosing spondylitis (93–95).